From the Research
Baxdrostat is a promising treatment for chronic kidney disease (CKD), particularly in patients with resistant hypertension, as it inhibits aldosterone synthase, reducing aldosterone levels and helping to lower blood pressure, with no significant impact on systemic exposure or clearance in patients with kidney disease, as shown in a recent study 1.
Key Points
- Baxdrostat works by inhibiting aldosterone synthase, which reduces aldosterone levels and helps lower blood pressure.
- For CKD patients, baxdrostat may be started at a dose of 10 mg once daily, with potential dose adjustments based on blood pressure response and tolerability, as indicated in the phase 1 study 1.
- Treatment is ongoing as CKD is a chronic condition.
- When using baxdrostat, regular monitoring of kidney function, potassium levels, and blood pressure is essential, as hyperkalemia can occur.
- Baxdrostat addresses a key mechanism in CKD progression by reducing aldosterone, which contributes to kidney damage through inflammation, fibrosis, and sodium retention.
Benefits and Considerations
- By controlling blood pressure and reducing aldosterone's harmful effects, baxdrostat may help slow CKD progression beyond what traditional antihypertensives can achieve.
- This medication is particularly valuable for CKD patients who haven't responded adequately to standard treatments.
- The study 1 demonstrated that baxdrostat has a similar pharmacokinetic profile in patients with varying degrees of renal function, suggesting that dose adjustment due to PK differences in patients with kidney disease is unnecessary.
- Other studies, such as 2, discuss the current standards of treatment for hypertension in CKD patients and highlight the potential benefits of emerging agents like baxdrostat.